FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Nicholas Dean

Research Profile

Chemicals & Drugs

Anatomy

Living Beings

Mouse
Rats

Physiology

Co-author Network

Publications

TOP 3
Mark Sisco; Zol B Kryger; Kristina D O'Shaughnessy; Peter S Kim; Gregory Schultz; Xian-Zhong Ding; Nakshatra K Roy; Nicholas Dean; Thomas A Mustoe
Antisense inhibition of connective tissue growth factor (CTGF/CCN2) mRNA limits hypertrophic scarring without affecting wound healing in vivo.
Jeremy R Graff; Bruce W Konicek; Thomas M Vincent; Rebecca L Lynch; David Monteith; Spring N Weir; Phil Schwier; Andrew Capen; Robin L Goode; Michele S Dowless; Yuefeng Chen; Hong Zhang; Sean Sissons; Karen Cox; Ann M McNulty; Stephen H Parsons; Tao Wang; Lillian Sams; Sandaruwan Geeganage; Larry E Douglass; Blake Lee Neubauer; Nicholas Dean; Kerry Blanchard; Jianyong Shou; Louis F Stancato; Julia H Carter; Eric G Marcusson
Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity.
Youngsoo Kim; Joon Won Yoon; Xiaokun Xiao; Nicholas Dean; Brett P Monia; Eric G Marcusson
Selective down-regulation of glioma-associated oncogene 2 inhibits the proliferation of hepatocellular carcinoma cells.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Nicholas Dean (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2008: Mark Sisco; Zol B Kryger; Kristina D O'Shaughnessy; Peter S Kim; Gregory Schultz; Xian-Zhong Ding; Nakshatra K Roy; Nicholas Dean; Thomas A Mustoe
Antisense inhibition of connective tissue growth factor (CTGF/CCN2) mRNA limits hypertrophic scarring without affecting wound healing in vivo.
Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society 2008;16(5):661-73.
2007: Jeremy R Graff; Bruce W Konicek; Thomas M Vincent; Rebecca L Lynch; David Monteith; Spring N Weir; Phil Schwier; Andrew Capen; Robin L Goode; Michele S Dowless; Yuefeng Chen; Hong Zhang; Sean Sissons; Karen Cox; Ann M McNulty; Stephen H Parsons; Tao Wang; Lillian Sams; Sandaruwan Geeganage; Larry E Douglass; Blake Lee Neubauer; Nicholas Dean; Kerry Blanchard; Jianyong Shou; Louis F Stancato; Julia H Carter; Eric G Marcusson
Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity.
The Journal of clinical investigation 2007;117(9):2638-48.
2007: Youngsoo Kim; Joon Won Yoon; Xiaokun Xiao; Nicholas Dean; Brett P Monia; Eric G Marcusson
Selective down-regulation of glioma-associated oncogene 2 inhibits the proliferation of hepatocellular carcinoma cells.
Cancer research 2007;67(8):3583-93.
2006: Kathy Bonness; Ileana V Aragon; Beth Rutland; Solomon F Ofori-Acquah; Nicholas Dean; Richard E Honkanen
Cantharidin-induced mitotic arrest is associated with the formation of aberrant mitotic spindles and lagging chromosomes resulting, in part, from the suppression of PP2Aalpha.
Molecular cancer therapeutics 2006;5(11):2727-36.
2006: Bing Z Carter; Duncan H Mak; Yuexi Shi; Wendy D Schober; Rui-Yu Wang; Marina Konopleva; Erich Koller; Nicholas Dean; Michael Andreeff
Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance.
Cell cycle (Georgetown, Tex.) 2006;5(19):2223-9.
2006: Ranjan J Perera; Seongjoon Koo; C Frank Bennett; Nicholas Dean; Nitin Gupta; Jian-Zhong Qin; Brian J Nickoloff
Defining the transcriptome of accelerated and replicatively senescent keratinocytes reveals links to differentiation, interferon signaling, and Notch related pathways.
Journal of cellular biochemistry 2006;98(2):394-408.
2006: Timothy A Vickers; Hong Zhang; Mark J Graham; Kristina M Lemonidis; Chenguang Zhao; Nicholas Dean
Modification of MyD88 mRNA splicing and inhibition of IL-1beta signaling in cell culture and in mice with a 2'-O-methoxyethyl-modified oligonucleotide.
Journal of immunology (Baltimore, Md. : 1950) 2006;176(6):3652-61.
2006: Ranjan J Perera; Eric G Marcusson; Seongjoon Koo; Xiaolin Kang; Youngsoo Kim; Neill White; Nicholas Dean
Identification of novel PPARgamma target genes in primary human adipocytes.
Gene 2006;369():90-9.
2006: Erich Koller; Stephanie Propp; Hong Zhang; Chenguang Zhao; Xiaokun Xiao; MingYi Chang; Scott A Hirsch; Peter J Shepard; Seongjoon Koo; Cain Murphy; Robert I Glazer; Nicholas Dean
Use of a chemically modified antisense oligonucleotide library to identify and validate Eg5 (kinesin-like 1) as a target for antineoplastic drug development.
Cancer research 2006;66(4):2059-66.
2006: Erich Koller; Stephanie Propp; Heather Murray; Walt F Lima; Balkrishen Bhat; Thazha P Prakash; Charles R Allerson; Eric E Swayze; Eric G Marcusson; Nicholas Dean
Competition for RISC binding predicts in vitro potency of siRNA.
Nucleic acids research 2006;34(16):4467-76.
2005: Ji Zhang; Shideng Bao; Ryohei Furumai; Katerina S Kucera; Ambereen Ali; Nicholas Dean; Xiao-Fan Wang
Protein phosphatase 5 is required for ATR-mediated checkpoint activation.
Molecular and cellular biology 2005;25(22):9910-9.
2005: Stephan Gysin; Sang-Hyun Lee; Nicholas Dean; Martin McMahon
Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.
Cancer research 2005;65(11):4870-80.
2004: Christine Esau; Xiaolin Kang; Eigen Peralta; Elaine Hanson; Eric G Marcusson; Lingamanaidu V Ravichandran; Yingqing Sun; Seongjoon Koo; Ranjan J Perera; Ravi Jain; Nicholas Dean; Susan M Freier; C Frank Bennett; Bridget Lollo; Richard H Griffey
MicroRNA-143 regulates adipocyte differentiation.
The Journal of biological chemistry 2004;279(50):52361-5.
2004: Teresa Golden; Ileana V Aragon; Guofei Zhou; Scott R Cooper; Nicholas Dean; Richard E Honkanen
Constitutive over expression of serine/threonine protein phosphatase 5 (PP5) augments estrogen-dependent tumor growth in mice.
Cancer letters 2004;215(1):95-100.
2004: Scott P Henry; Eric G Marcusson; Thomas M Vincent; Nicholas Dean
Setting sights on the treatment of ocular angiogenesis using antisense oligonucleotides.
Trends in pharmacological sciences 2004;25(10):523-7.
2004: Phillip J Gray; David J Bearss; Haiyong Han; Raymond B Nagle; Ming Tsao; Nicholas Dean; Daniel Von Hoff
Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer.
Molecular cancer therapeutics 2004;3(5):641-6.
2004: Ambereen Ali; Ji Zhang; Shideng Bao; Irene Liu; Diane M Otterness; Nicholas Dean; Robert T Abraham; Xiao-Fan Wang
Requirement of protein phosphatase 5 in DNA-damage-induced ATM activation.
Genes & development 2004;18(3):249-54.
2004: Yingqing Sun; Seongjoon Koo; Neill White; Eigen Peralta; Christine Esau; Nicholas Dean; Ranjan J Perera
Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs.
Nucleic acids research 2004;32(22):e188.
2004: Lingamanaidu V Ravichandran; Nicholas Dean; Eric G Marcusson
Use of antisense oligonucleotides in functional genomics and target validation.
Oligonucleotides 2004;14(1):49-64.
2004: Kozue Uchio; Mark Graham; Nicholas Dean; Jean Rosenbaum; Alexis Desmoulière
Down-regulation of connective tissue growth factor and type I collagen mRNA expression by connective tissue growth factor antisense oligonucleotide during experimental liver fibrosis.
Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society 2004;12(1):60-6.
2003: Nicholas Dean; C Frank Bennett
Antisense oligonucleotide-based therapeutics for cancer.
Oncogene 2003;22(56):9087-96.
2003: Julie T Daniels; Gregory Schultz; Timothy Blalock; Qian Garrett; Gary Grotendorst; Nicholas Dean; Peng Khaw
Mediation of transforming growth factor-beta(1)-stimulated matrix contraction by fibroblasts: a role for connective tissue growth factor in contractile scarring.
The American journal of pathology 2003;163(5):2043-52.
2003: Bing Z Carter; Michele Milella; Twee Tsao; Teresa McQueen; Wendy D Schober; Wei Hu; Nicholas Dean; Linda Steelman; James A McCubrey; Michael Andreeff
Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia.
Leukemia 2003;17(11):2081-9.
2003: Hong Zhang; Jennifer Taylor; Doreen Luther; Joe Johnston; Susan Murray; Jacqueline R Wyatt; Andrew T Watt; Seongjoon Koo; Cathie York-DeFalco; Kimberly Stecker; Nicholas Dean
Antisense oligonucleotide inhibition of Bcl-xL and Bid expression in liver regulates responses in a mouse model of Fas-induced fulminant hepatitis.
The Journal of pharmacology and experimental therapeutics 2003;307(1):24-33.
2003: Gudrun Urban; Teresa Golden; Ileana V Aragon; Lex Cowsert; Scott R Cooper; Nicholas Dean; Richard E Honkanen
Identification of a functional link for the p53 tumor suppressor protein in dexamethasone-induced growth suppression.
The Journal of biological chemistry 2003;278(11):9747-53.
2003: Timothy A Vickers; Seongjoon Koo; C Frank Bennett; Stanley T Crooke; Nicholas Dean; Brenda F Baker
Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis.
The Journal of biological chemistry 2003;278(9):7108-18.
2003: Niketa A Patel; Duane C Eichler; David S Chappell; Philip A Illingworth; Charles E Chalfant; Mayumi Yamamoto; Nicholas Dean; Jacqueline R Wyatt; Konrad Mebert; James E Watson; Denise R Cooper
The protein kinase C beta II exon confers mRNA instability in the presence of high glucose concentrations.
The Journal of biological chemistry 2003;278(2):1149-57.
2003: Zongyou Chen; Lina Lu; Hong Zhang; Nicholas Dean; John J Fung; Shiguang Qian
Administration of antisense oligodeoxyribonucleotides targeting NF-kappaB prolongs allograft survival via suppression of cytotoxicity.
Microsurgery 2003;23(5):494-7.
2003: Yong-Min Yang; Frédéric Bost; Wilfried Charbono; Nicholas Dean; Robert McKay; Johng S Rhim; Chantal Depatie; Dan Mercola
C-Jun NH(2)-terminal kinase mediates proliferation and tumor growth of human prostate carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1):391-401.
2003: M Francesca Cordeiro; Anna L Mead; Robin R Ali; Robert Andrew Alexander; S Murray; C Chen; Cathie York-DeFalco; Nicholas Dean; Gregory Schultz; Peng Khaw
Novel antisense oligonucleotides targeting TGF-beta inhibit in vivo scarring and improve surgical outcome.
Gene therapy 2003;10(1):59-71.
2002: Gouri Ranganathan; Wei Song; Nicholas Dean; Brett P Monia; Steven W Barger; Philip Alfred Kern
Regulation of lipoprotein lipase by protein kinase C alpha in 3T3-F442A adipocytes.
The Journal of biological chemistry 2002;277(41):38669-75.
2002: Sophie Derenne; Brett P Monia; Nicholas Dean; Jennifer Taylor; Marie-Josée Rapp; Jean-Luc Harousseau; Régis Bataille; Martine Amiot
Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.
Blood 2002;100(1):194-9.
2002: Yoon-Jin Lee; Jae-Won Soh; Nicholas Dean; Chul-Koo Cho; Tae-Hwan Kim; Su-Jun Lee; Yun-Sil Lee
Protein kinase Cdelta overexpression enhances radiation sensitivity via extracellular regulated protein kinase 1/2 activation, abolishing the radiation-induced G(2)-M arrest.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 2002;13(5):237-46.
2002: Bin Pan; Kang-Shen Yao; Brett P Monia; Nicholas Dean; Robert A McKay; Thomas C Hamilton; Peter J O'Dwyer
Reversal of cisplatin resistance in human ovarian cancer cell lines by a c-jun antisense oligodeoxynucleotide (ISIS 10582): evidence for the role of transcription factor overexpression in determining resistant phenotype.
Biochemical pharmacology 2002;63(9):1699-707.
2002: Madeline Butler; Robert A McKay; Ian J Popoff; William A Gaarde; Donna R Witchell; Susan F Murray; Nicholas Dean; Sanjay Bhanot; Brett P Monia
Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice.
Diabetes 2002;51(4):1028-34.
2002: Bryone J Kuss; Marguerite Corbo; Wen Min Lau; Dean A Fennell; Nicholas Dean; Finbarr E Cotter
In vitro and in vivo downregulation of MRP1 by antisense oligonucleotides: a potential role in neuroblastoma therapy.
International journal of cancer. Journal international du cancer 2002;98(1):128-33.
2002: H Elizabeth Broome; Alice L Yu; Mitchell B Diccianni; Bruce M Camitta; Brett P Monia; Nicholas Dean
Inhibition of Bcl-xL expression sensitizes T-cell acute lymphoblastic leukemia cells to chemotherapeutic drugs.
Leukemia research 2002;26(3):311-6.
2002: Xiao-Ying Hua; A Moore; Shelle Malkmus; S F Murray; Nicholas Dean; Tony L Yaksh; M Butler
Inhibition of spinal protein kinase Calpha expression by an antisense oligonucleotide attenuates morphine infusion-induced tolerance.
Neuroscience 2002;113(1):99-107.
2002: Teresa Golden; Nicholas Dean; Richard E Honkanen
Use of antisense oligonucleotides: advantages, controls, and cardiovascular tissue.
Microcirculation (New York, N.Y. : 1994) 2002;9(1):51-64.
2001: Nicholas Dean
Functional genomics and target validation approaches using antisense oligonucleotide technology.
Current opinion in biotechnology 2001;12(6):622-5.
2001: Hajime Higuchi; H Miyoshi; Steven F Bronk; H Zhang; Nicholas Dean; Gregory J Gores
Bid antisense attenuates bile acid-induced apoptosis and cholestatic liver injury.
The Journal of pharmacology and experimental therapeutics 2001;299(3):866-73.
2001: H Zhang; Nicholas Dean
Oligonucleotide inhibition of Fas as a potential treatment strategy in human liver disease.
Drug news & perspectives 2001;14(8):453-9.
2001: GH Brough; Songwei Wu; Donna L Cioffi; Timothy Moore; M Li; Nicholas Dean; Troy Stevens
Contribution of endogenously expressed Trp1 to a Ca2+-selective, store-operated Ca2+ entry pathway.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2001;15(10):1727-38.
2001: Gudrun Urban; Teresa Golden; Ileana V Aragon; Jonathan G Scammell; Nicholas Dean; Richard E Honkanen
Identification of an estrogen-inducible phosphatase (PP5) that converts MCF-7 human breast carcinoma cells into an estrogen-independent phenotype when expressed constitutively.
The Journal of biological chemistry 2001;276(29):27638-46.
2001: Niketa A Patel; Charles E Chalfant; James E Watson; Jacqueline R Wyatt; Nicholas Dean; Duane C Eichler; Denise R Cooper
Insulin regulates alternative splicing of protein kinase C beta II through a phosphatidylinositol 3-kinase-dependent pathway involving the nuclear serine/arginine-rich splicing factor, SRp40, in skeletal muscle cells.
The Journal of biological chemistry 2001;276(25):22648-54.
2001: Alexander R Gottschalk; Daniel Basila; M Wong; Nicholas Dean; Christian H Brandts; David Stokoe; Daphne A Haas-Kogan
p27Kip1 is required for PTEN-induced G1 growth arrest.
Cancer research 2001;61(5):2105-11.
2001: Dean A Fennell; Marguerite Corbo; Nicholas Dean; B P Monia; Finbarr E Cotter
In vivo suppression of Bcl-XL expression facilitates chemotherapy-induced leukaemia cell death in a SCID/NOD-Hu model.
British journal of haematology 2001;112(3):706-13.
2001: Zhengrong Yu; Hong Zhang; Richard S Geary; M Graham; Lilit Masarjian; Kristina M Lemonidis; Rosanne M Crooke; Nicholas Dean; Arthur A Levin
Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice.
The Journal of pharmacology and experimental therapeutics 2001;296(2):388-95.
2001: Jennifer Taylor; Scott R Cooper; Nicholas Dean
Antisense oligonucleotides as research tools.
Methods in molecular medicine 2001;61():99-106.
2001: D A Dean; Gudrun Urban; Ileana V Aragon; Mark R Swingle; B Miller; S Rusconi; M Bueno; Nicholas Dean; Richard E Honkanen
Serine/threonine protein phosphatase 5 (PP5) participates in the regulation of glucocorticoid receptor nucleocytoplasmic shuttling.
BMC cell biology 2001;2():6.
2000: P Flynn; M Wongdagger; M Zavar; Nicholas Dean; David Stokoe
Inhibition of PDK-1 activity causes a reduction in cell proliferation and survival.
Current biology : CB 2000;10(22):1439-42.
2000: James G Karras; Robert A McKay; T Lu; Nicholas Dean; Brett P Monia
Antisense inhibition of membrane-bound human interleukin-5 receptor-alpha chain does not affect soluble receptor expression and induces apoptosis in TF-1 cells.
Antisense & nucleic acid drug development 2000;10(5):347-57.
2000: V Taylor; M Wong; Christian H Brandts; L Reilly; Nicholas Dean; Lex Cowsert; S Moodie; David Stokoe
5' phospholipid phosphatase SHIP-2 causes protein kinase B inactivation and cell cycle arrest in glioblastoma cells.
Molecular and cellular biology 2000;20(18):6860-71.
2000: Olga Potapova; Myriam Gorospe; Frédéric Bost; Nicholas Dean; William A Gaarde; Dan Mercola; Nikki J Holbrook
c-Jun N-terminal kinase is essential for growth of human T98G glioblastoma cells.
The Journal of biological chemistry 2000;275(32):24767-75.
2000: H Zhang; J Cook; J Nickel; R Yu; K Stecker; K Myers; Nicholas Dean
Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis.
Nature biotechnology 2000;18(8):862-7.
2000: James G Karras; Robert A McKay; Nicholas Dean; Brett P Monia
Deletion of individual exons and induction of soluble murine interleukin-5 receptor-alpha chain expression through antisense oligonucleotide-mediated redirection of pre-mRNA splicing.
Molecular pharmacology 2000;58(2):380-7.
2000: James G Karras; K McGraw; Robert A McKay; Scott R Cooper; D Lerner; T Lu; C Walker; Nicholas Dean; Brett P Monia
Inhibition of antigen-induced eosinophilia and late phase airway hyperresponsiveness by an IL-5 antisense oligonucleotide in mouse models of asthma.
Journal of immunology (Baltimore, Md. : 1950) 2000;164(10):5409-15.
2000: Kirill Rosen; Janusz Rak; T Leung; Nicholas Dean; Robert S Kerbel; Jorge Filmus
Activated Ras prevents downregulation of Bcl-X(L) triggered by detachment from the extracellular matrix. A mechanism of Ras-induced resistance to anoikis in intestinal epithelial cells.
The Journal of cell biology 2000;149(2):447-56.
2000: Olga Potapova; Myriam Gorospe; R H Dougherty; Nicholas Dean; William A Gaarde; Nikki J Holbrook
Inhibition of c-Jun N-terminal kinase 2 expression suppresses growth and induces apoptosis of human tumor cells in a p53-dependent manner.
Molecular and cellular biology 2000;20(5):1713-22.
2000: A Cheng; Nicholas Dean; Richard E Honkanen
Serine/threonine protein phosphatase type 1gamma1 is required for the completion of cytokinesis in human A549 lung carcinoma cells.
The Journal of biological chemistry 2000;275(3):1846-54.
2000: K J Myers; Nicholas Dean
Sensible use of antisense: how to use oligonucleotides as research tools.
Trends in pharmacological sciences 2000;21(1):19-23.
2000: Frédéric Bost; Robert McKay; Nicholas Dean; Olga Potapova; Dan Mercola
Antisense methods for discrimination of phenotypic properties of closely related gene products: Jun kinase family.
Methods in enzymology 2000;314():342-62.
1999: Jennifer Taylor; Q Q Zhang; Jacqueline R Wyatt; Nicholas Dean
Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides.
Nature biotechnology 1999;17(11):1097-100.
1999: Jennifer Taylor; Q Q Zhang; Brett P Monia; Eric G Marcusson; Nicholas Dean
Inhibition of Bcl-xL expression sensitizes normal human keratinocytes and epithelial cells to apoptotic stimuli.
Oncogene 1999;18(31):4495-504.
1999: Eric G Marcusson; Bruce R Yacyshyn; William R Shanahan; Nicholas Dean
Preclinical and clinical pharmacology of antisense oligonucleotides.
Molecular biotechnology 1999;12(1):1-11.
1999: Peter J Ferguson; Olga Collins; Nicholas Dean; Janice M DeMoor; C S Li; mark vincent; James Koropatnick
Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells.
British journal of pharmacology 1999;127(8):1777-86.
1999: Z Zuo; Gudrun Urban; Jonathan G Scammell; Nicholas Dean; T K McLean; Ileana V Aragon; Richard E Honkanen
Ser/Thr protein phosphatase type 5 (PP5) is a negative regulator of glucocorticoid receptor-mediated growth arrest.
Biochemistry 1999;38(28):8849-57.
1999: Scott R Cooper; Jennifer Taylor; Loren J Miraglia; Nicholas Dean
Pharmacology of antisense oligonucleotide inhibitors of protein expression.
Pharmacology & therapeutics 1999;82(2-3):427-35.
1999: Zsolt Jobbagy; Zoltan Olah; Gyorgy Petrovics; Maribeth V Eiden; B D Leverett; Nicholas Dean; Wayne B Anderson
Up-regulation of the Pit-2 phosphate transporter/retrovirus receptor by protein kinase C epsilon.
The Journal of biological chemistry 1999;274(11):7067-71.
1999: Jennifer Taylor; Nicholas Dean
Regulation of pre-mRNA splicing by antisense oligonucleotides.
Current opinion in drug discovery & development 1999;2(2):147-51.
1999: Frédéric Bost; Robert McKay; M Bost; Olga Potapova; Nicholas Dean; Dan Mercola
The Jun kinase 2 isoform is preferentially required for epidermal growth factor-induced transformation of human A549 lung carcinoma cells.
Molecular and cellular biology 1999;19(3):1938-49.
1999: L Shen; Nicholas Dean; Robert I Glazer
Induction of p53-dependent, insulin-like growth factor-binding protein-3-mediated apoptosis in glioblastoma multiforme cells by a protein kinase Calpha antisense oligonucleotide.
Molecular pharmacology 1999;55(2):396-402.
1999: Robert A McKay; Loren J Miraglia; Lendell L Cummins; S R Owens; H Sasmor; Nicholas Dean
Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression.
The Journal of biological chemistry 1999;274(3):1715-22.
1998: Suresh K Alahari; Robert DeLong; M H Fisher; Nicholas Dean; P Viliet; Rudy L Juliano
Novel chemically modified oligonucleotides provide potent inhibition of P-glycoprotein expression.
The Journal of pharmacology and experimental therapeutics 1998;286(1):419-28.
1998: J U Dennis; Nicholas Dean; C F Bennett; James W Griffith; C Max Lang; Danny R Welch
Human melanoma metastasis is inhibited following ex vivo treatment with an antisense oligonucleotide to protein kinase C-alpha.
Cancer letters 1998;128(1):65-70.
1998: Z Zuo; Nicholas Dean; Richard E Honkanen
Serine/threonine protein phosphatase type 5 acts upstream of p53 to regulate the induction of p21(WAF1/Cip1) and mediate growth arrest.
The Journal of biological chemistry 1998;273(20):12250-8.
1998: Eric G Marcusson; Balkrishen Bhat; Muthiah Manoharan; C Frank Bennett; Nicholas Dean
Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus.
Nucleic acids research 1998;26(8):2016-23.
1998: Nicholas Dean; Robert A McKay; J Holmlund
Antisense oligonucleotides as inhibitors of genes that regulate AP-1: pharmacology and clinical development.
Antisense & nucleic acid drug development 1998;8(2):147-51.
1998: T Geiger; M Müller; Nicholas Dean; Doriano Fabbro
Antitumor activity of a PKC-alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice.
Anti-cancer drug design 1998;13(1):35-45.
1997: Frédéric Bost; Robert McKay; Nicholas Dean; Dan Mercola
The JUN kinase/stress-activated protein kinase pathway is required for epidermal growth factor stimulation of growth of human A549 lung carcinoma cells.
The Journal of biological chemistry 1997;272(52):33422-9.
1997: O Traub; Brett P Monia; Nicholas Dean; B C Berk
PKC-epsilon is required for mechano-sensitive activation of ERK1/2 in endothelial cells.
The Journal of biological chemistry 1997;272(50):31251-7.
1997: K McGraw; R McKay; Loren J Miraglia; RT Boggs; J P Pribble; M Muller; T Geiger; D Fabbro; Nicholas Dean
Antisense oligonucleotide inhibitors of isozymes of protein kinase C: in vitro and in vivo activity, and clinical development as anti-cancer therapeutics.
Anti-cancer drug design 1997;12(5):315-26.
1997: Nicholas Dean; R H Griffey
Identification and characterization of second-generation antisense oligonucleotides.
Antisense & nucleic acid drug development 1997;7(3):229-33.
1997: D F Liao; B Monia; Nicholas Dean; Bradford C Berk
Protein kinase C-zeta mediates angiotensin II activation of ERK1/2 in vascular smooth muscle cells.
The Journal of biological chemistry 1997;272(10):6146-50.
1997: L Levesque; Nicholas Dean; H Sasmor; Stanley T Crooke
Antisense oligonucleotides targeting human protein kinase C-alpha inhibit phorbol ester-induced reduction of bradykinin-evoked calcium mobilization in A549 cells.
Molecular pharmacology 1997;51(2):209-16.
1997: Y S Lee; Andrzej Dlugosz; R McKay; Nicholas Dean; Stuart H Yuspa
Definition by specific antisense oligonucleotides of a role for protein kinase C alpha in expression of differentiation markers in normal and neoplastic mouse epidermal keratinocytes.
Molecular carcinogenesis 1997;18(1):44-53.
1996: Suresh K Alahari; Nicholas Dean; M H Fisher; Robert DeLong; Muthiah Manoharan; K L Tivel; Rudy L Juliano
Inhibition of expression of the multidrug resistance-associated P-glycoprotein of by phosphorothioate and 5' cholesterol-conjugated phosphorothioate antisense oligonucleotides.
Molecular pharmacology 1996;50(4):808-19.
1996: K H Altmann; D Fabbro; Nicholas Dean; T Geiger; Brett P Monia; M Müller; P Nicklin
Second-generation antisense oligonucleotides: structure-activity relationships and the design of improved signal-transduction inhibitors.
Biochemical Society transactions 1996;24(3):630-7.
1996: Nicholas Dean; R McKay; Loren J Miraglia; T Geiger; M Müller; D Fabbro; C Frank Bennett
Antisense oligonucleotides as inhibitors of signal transduction: development from research tools to therapeutic agents.
Biochemical Society transactions 1996;24(3):623-9.
1996: Nicholas Dean; R McKay; Loren J Miraglia; R Howard; S Cooper; J Giddings; P Nicklin; L Meister; R Ziel; T Geiger; M Muller; D Fabbro
Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression.
Cancer research 1996;56(15):3499-507.
1996: T Yazaki; S Ahmad; ali chahlavi; E Zylber-Katz; Nicholas Dean; samuel rabkin; Robert L Martuza; Robert I Glazer
Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide.
Molecular pharmacology 1996;50(2):236-42.
1996: Loren J Miraglia; T Geiger; C Frank Bennett; Nicholas Dean
Inhibition of interleukin-1 type I receptor expression in human cell-lines by an antisense phosphorothioate oligodeoxynucleotide.
International journal of immunopharmacology 1996;18(4):227-40.
1996: A J Stewart; Yvan Canitrot; E Baracchini; Nicholas Dean; Roger G Deeley; SUSAN COLE
Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate oligonucleotides.
Biochemical pharmacology 1996;51(4):461-9.
1996: Robert A McKay; Lendell L Cummins; M J Graham; Elena A Lesnik; S R Owens; M Winniman; Nicholas Dean
Enhanced activity of an antisense oligonucleotide targeting murine protein kinase C-alpha by the incorporation of 2'-O-propyl modifications.
Nucleic acids research 1996;24(3):411-7.
1995: Nicholas Dean; A L Boynton
EGF-induced increase in diacylglycerol, choline release, and DNA synthesis is extracellular calcium dependent.
Journal of cellular physiology 1995;164(3):449-58.
1994: Nicholas Dean; R McKay
Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(24):11762-6.
1994: Nicholas Dean; R McKay; Tom Condon; C Frank Bennett
Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters.
The Journal of biological chemistry 1994;269(23):16416-24.
1991: Nicholas Dean; L J Mordan; K Tse; Susan Mooberry; Alton Boynton
Okadaic acid inhibits PDGF-induced proliferation and decreases PDGF receptor number in C3H/10T1/2 mouse fibroblasts.
Carcinogenesis 1991;12(4):665-70.
1990: Alton Boynton; Nicholas Dean; T D Hill
Inositol 1,3,4,5-tetrakisphosphate and regulation of intracellular calcium.
Biochemical pharmacology 1990;40(9):1933-9.
1990: T D Hill; Alton Boynton; Nicholas Dean; L J Mordan
Retinyl acetate inhibits platelet-derived growth factor-induced Ca2+ signals in C3H 10T1/2 fibroblasts.
Journal of cellular physiology 1990;144(2):229-36.
1990: Nicholas Dean; Alton Boynton
Angiotensin II causes phosphatidylinositol turnover and increases 1,2-diacylglycerol mass but is not mitogenic in rat liver T51B cells.
The Biochemical journal 1990;269(2):347-52.
1990: T D Hill; Nicholas Dean; L J Mordan; A F Lau; MY Kanemitsu; Alton Boynton
PDGF-induced activation of phospholipase C is not required for induction of DNA synthesis.
Science (New York, N.Y.) 1990;248(4963):1660-3.
1990: L J Mordan; Nicholas Dean; Richard E Honkanen; Alton Boynton
Okadaic acid: a reversible inhibitor of neoplastic transformation of mouse fibroblasts.
Cancer communications 1990;2(7):237-41.
1989: Nicholas Dean; MY Kanemitsu; Alton Boynton
Effects of the tyrosine-kinase inhibitor genistein on DNA synthesis and phospholipid-derived second messenger generation in mouse 10T1/2 fibroblasts and rat liver T51B cells.
Biochemical and biophysical research communications 1989;165(2):795-801.
1989: Nicholas Dean; M A Beaven
Methods for the analysis of inositol phosphates.
Analytical biochemistry 1989;183(2):199-209.
1988: T D Hill; Nicholas Dean; Alton Boynton
Inositol 1,3,4,5-tetrakisphosphate induces Ca2+ sequestration in rat liver cells.
Science (New York, N.Y.) 1988;242(4882):1176-8.
1988: José Renan Cunha-Melo; Nicholas Dean; H Ali; Michael A Beaven
Formation of inositol 1,4,5-trisphosphate and inositol 1,3,4-trisphosphate from inositol 1,3,4,5-tetrakisphosphate and their pathways of degradation in RBL-2H3 cells.
The Journal of biological chemistry 1988;263(28):14245-50.
1988: Nicholas Dean; J D Moyer
Metabolism of inositol bis-, tris-, tetrakis- and pentakis-phosphates in GH3 cells.
The Biochemical journal 1988;250(2):493-500.
1987: José Renan Cunha-Melo; Nicholas Dean; J D Moyer; K Maeyama; Michael A Beaven
The kinetics of phosphoinositide hydrolysis in rat basophilic leukemia (RBL-2H3) cells varies with the type of IgE receptor cross-linking agent used.
The Journal of biological chemistry 1987;262(24):11455-63.
1987: J D Moyer; O Reizes; Nicholas Dean; N Malinowski
D-myo-inositol (1,4)-bisphosphate 1-phosphate. Partial purification from rat liver and characterization.
Biochemical and biophysical research communications 1987;146(3):1018-26.
1987: Nicholas Dean; J D Moyer
Separation of multiple isomers of inositol phosphates formed in GH3 cells.
The Biochemical journal 1987;242(2):361-6.